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The c-Jun NH(2)-terminal kinase (JNK) is a critical
determinant of obesity-associated inflammation
and glucose intolerance. The upstream mechanisms
controlling this pathway are still unknown. Here we
report that the levels of the PB1 domain-containing
adaptor NBR1 correlated with the expression of
proinflammatory molecules in adipose tissue from
human patients with metabolic syndrome, suggest-
ing that NBR1 plays a key role in adipose-tissue
inflammation. We also show that NBR1 inactivation
in the myeloid compartment impairs the function,
M1 polarization, and chemotactic activity of macro-
phages; prevents inflammation of adipose tissue;
and improves glucose tolerance in obese mice.
Furthermore, we demonstrate that an interaction
between the PB1 domains of NBR1 and the
mitogen-activated kinase kinase 3 (MEKK3) enables
the formation of a signaling complex required for
the activation of JNK. Together, these discoveries
identify an NBR1-MEKK3 complex as a key regulator
of JNK signaling and adipose tissue inflammation in
obesity.
INTRODUCTION
Obesity is an international healthcare priority due to its
increasing prevalence and its association with glucose intoler-
ance (Spiegel and Nabel, 2006; Yach et al., 2006). The lack of
a complete understanding of the precise regulatory networks
that control adipogenesis, energy expenditure, and inflammation
is a fundamental problem in metabolic research. It is clear also
that obesity-induced inflammation underlies critical aspects of
glucose metabolism deregulation and insulin resistance (Glass
and Olefsky, 2012; Gregor and Hotamisligil, 2011). We recently
identified a signaling molecule that plays important roles in
obesity and the inflammation and glucose intolerance thatCell Medevelop in the context of this condition. Specifically, genetic
ablation of the signaling adaptor p62 (also known as sequesto-
some 1) in mice resulted in mature-onset obesity, adipose
inflammation, and glucose intolerance (Rodriguez et al., 2006).
Notably, p62 is a member of the PB1 domain-containing
signaling network, which also includes kinases such as protein
kinase C z (PKCz), mitogen-activated protein kinase kinase 2
(MEKK2), and MEKK3, as well as adapters such as partition-
ing-defective protein 6 (Par6) and NBR1 (Moscat et al., 2006).
It is believed that p62 can interact alternatively with PKCz or
NBR1 through their respective PB1 domains, but the physiolog-
ical role and mechanisms of action of NBR1 in vivo have not yet
been clarified (Moscat and Diaz-Meco, 2011; Moscat et al.,
2006, 2007, 2009). Although PKCz-deficient mice do not show
alterations in adiposity as compared to wild-type (WT) mice
when both are fed with high-fat diet (HFD), PKCz-deficient
mice showed increased adipose inflammation and impaired
glucose tolerance (Lee et al., 2010).
Our data on p62 knockout (KO) mice and cells have demon-
strated that p62 is a critical negative regulator of white adipose
tissue (WAT) adipogenesis but is a positive regulator of brown
adipose tissue (BAT) function, through the negative regulation
of ERK1 and the positive regulation of p38, respectively (Mu¨ller
et al., 2013). This model explains why the adipose-specific abla-
tion of p62 in mice results not only in an increase in adiposity but
also impaired nonshivering thermogenesis, which in turn leads to
a decrease in themetabolic rate (Mu¨ller et al., 2013). The fact that
PKCz is a negative regulator of obesity-induced inflammation is
of great functional relevance, since recent studies have high-
lighted the importance of inflammation in the induction of
glucose intolerance in obese mice (Hotamisligil, 2006; Qatanani
and Lazar, 2007; Schenk et al., 2008; Shoelson et al., 2006; Sol-
inas et al., 2007). Also, experiments from a number of research
groups have demonstrated that the ablation of macrophages in
mice normalizes glucose homeostasis in the context of obesity
(Gordon, 2003; Gordon and Taylor, 2005; Lumeng et al.,
2007a, 2007b, 2007c; Mantovani et al., 2004; Patsouris et al.,
2008). Interestingly, selective genetic inactivation of p62 in the
myeloid compartment using cell-specific Cre mouse lines re-
vealed that p62 does not have an impact on macrophages in
the adipose tissue of obesemice (Mu¨ller et al., 2013). This findingtabolism 20, 499–511, September 2, 2014 ª2014 Elsevier Inc. 499
Figure 1. NBR1 Transcripts Levels Correlate with Adipose Inflam-
mation in Obese Patients
(A–F) Positive correlation between transcript levels of NBR1 and PPARg1 (A),
PPARg2 (B), CD68 (C), CD163 (D), MIP-1 (E), and MCP-1 (F) in obese patients.
See also Table S1.
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deficient mouse is secondary to increased adiposity and not due
to a potential role of p62 in the myeloid compartment.
The domain organization of NBR1 is remarkably similar to
that of p62, featuring PB1, zinc-finger, and UBA domains. The
outcomes of overexpression and transfection studies have sug-
gested that NBR1 is involved in growth-factor trafficking (Marda-
kheh et al., 2009) and/or p62-mediated processes (Kirkin et al.,
2009; Lange et al., 2005; Yang et al., 2010). However, its precise
in vivo contribution to the control of metabolic homeostasis and/
or the ensuing inflammation in the context of obesity has not
been investigated. It is possible that p62, PKCz, and NBR1
play different roles in the control of metabolic homeostasis de-
pending on cell type. Here, we have characterized the effect of
myeloid-specific NBR1 ablation and found that this protein plays
a critical role in the regulation of macrophage polarization toward
the M1 phenotype during obesity-induced inflammation. Our500 Cell Metabolism 20, 499–511, September 2, 2014 ª2014 Elseviestudies in human patients with metabolic syndrome revealed a
significantly positive correlation between NBR1 transcript levels
and markers of metabolic alterations and inflammation. These
results establish that NBR1 plays a critical role in obesity-
induced glucose intolerance, and that this is due to its impact
on macrophage function. They also highlight the relevance of
the PB1 network comprised of p62, PKCz and NBR1 at the
cellular interface between metabolism and inflammation.
RESULTS
High NBR1 Levels Correlate with Obesity in Human
Patients
The initial evidence of a possible connection between NBR1 and
abnormalities in metabolic homeostasis and obesity-induced
inflammation came from our analysis of adipose tissues from
two cohorts of human patients. The first consisted of 63 young
and basically healthy men and women with a wide range of
body mass index (BMI) and body fat values (see Ukropcova
et al., 2007 for subject characteristics). We found a positive
and significant statistical correlation between NBR1 and PPARg
(r = 0.36, p = 0.003) transcript levels in this cohort (data not
shown), which suggested that NBR1 and PPARg could act in
the same pathway to control metabolic homeostasis in adipose
tissue of obese but generally healthy patients. This conclusion
was supported by analysis of a second cohort, which consisted
of 44 middle-aged men with NCEP-defined ‘‘metabolic syn-
drome’’ (Grundy et al., 2004) (Table S1 available online). This
population is characterized bymore adipose tissue inflammation
than the healthy population in the study described above, andwe
found a highly significant positive correlation between NBR1
transcript levels and not only PPARg1 and PPARg2 (Figures 1A
and 1B) but also markers of the monocyte and macrophage line-
age, such as CD68 and CD163 (Figures 1C and 1D). Notably, the
latter have been validated as markers of macrophage infiltration
based on immunohistochemistry (data not shown). Significant
correlations were also found with transcripts encoding chemo-
kines and proinflammatory proteins like MCP-1 and MIP-1 (Fig-
ures 1E and 1F). These results suggest a potential role of NBR1 in
obesity-induced inflammation.
NBR1 in the Myeloid Compartment Plays a Critical Role
in Obesity-Induced Inflammation
Intrigued by the potential of a macrophage-based link between
NBR1, adipose tissue inflammation, and metabolic syndrome,
we next investigated the expression of NBR1 in the adipose
tissue of obese WT mice fed a HFD as compared to lean mice
fed a regular chow diet (RD). Double immunofluorescence of
NBR1 and themacrophagemarker F4/80 showedNBR1 staining
exclusively in crown-like structures that colocalized with F4/80
mostly in the HFD adipose sections, which indicates that
NBR1 is specifically expressed in macrophages that infiltrate
obese adipose tissue (Figure 2A). Consistent with this, NBR1
mRNA levels were significantly increased in adipose tissue
macrophages (ATMs) isolated from obese as compared to lean
mice (Figure 2B). Therefore, to address the role of NBR1 in adi-
pose tissue inflammation in vivo, we generated mice in which
NBR1 was genetically and selectively inactivated in the myeloid
cell compartment. Specifically NBR1fl/fl mice were crossed tor Inc.
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NBR1MyKO) and their corresponding NBR1fl/fl WT controls
were fed a HFD for 12 weeks, and body weight was monitored
continuously. The results in Figure 2C confirm that NBR1 was
effectively and selectively deleted from macrophages. The lack
of NBR1 in the myeloid compartment did not affect the body
weight or fat content of these mice, regardless of whether they
were fed the HFD (Figures 2D and 2E) or regular chow diet,
even when monitored over a longer period (data not shown).
However, in the mutant mice, macrophage recruitment to the
adipose tissue was significantly impaired (Figure 2F), and the
levels of inflammatory markers in the WAT were also reduced
(Figure 2G). Fluorescence-activated cell sorting (FACS) analysis
confirms a reduced presence of ATMs in theWAT ofmutantmice
(Figures 2H and S1A). It has been established that ATMs can
differentiate along different lineages, including the so-called
M1 and M2 (Gordon, 2003; Kang et al., 2008; Odegaard et al.,
2008; Vats et al., 2006), and an increase in the M1/M2 ratio
has been proposed to be responsible for glucose intolerance
responses in obese mice (Kang et al., 2008; Odegaard et al.,
2008). When isolated ATMs from WT and NBR1MyKO mice
were analyzed for several markers of macrophage differentia-
tion, it was clear that the loss of NBR1 selectively impaired
M1 polarization with a slight although reproducible increase in
M2 polarization (Figure 2I). Macrophage infiltration was also
inhibited in the livers fromNBR1MyKOmice as compared to iden-
tically treatedWT controls, as determined by the levels of macro-
phage transcript markers CD68 and F4/80 (Figure S1B). Results
of Figure S1C show that livers from KO mice displayed a reduc-
tion in the expression of genes associated with M1 polarization
(TNFa, IL-6, and MCP-1) and an increase in the expression of
the M2 polarization marker Mgl2. Of note, although not reaching
statistical significance, the circulating levels of TNFa and IL-6
were decreased in KOmice (Figure S1D). Furthermore, the levels
of circulating MCP1 were significantly decreased in the serum of
KO mice (Figure S1E), consistent with previously published
studies demonstrating the role of this chemokine in the recruit-
ment of inflammatory macrophages to obese adipose tissue (Ta-
kahashi et al., 2003).
NBR1 Deficiency in Macrophages Improves Glucose
Metabolism
In order to address whether the defects in macrophage polariza-
tion of mutant mice affect glucose homeostasis, HFD-fed
NBR1MyKOmice where compared to identically treatedWT con-
trols in terms of glucose tolerance and insulin response. As
demonstrated in Figure 3A, NBR1 deficiency in macrophages
resulted in improved glucose clearance in glucose tolerance
tests. Likewise, NBR1 deficiency in macrophages resulted in
improved insulin responses in insulin tolerance tests (Figure 3B)
and activation of Akt in liver, muscle, and WAT (Figure 3C). In
contrast, no differences were found in glucose tolerance and
insulin response assays between both mouse genotypes when
fed RD (Figures S2A and S2B). These findings suggest that a
lack of NBR1 in the myeloid compartment improves glucose
metabolism in the context of chronic HFD exposure. Consistent
with this, fasting basal glucose (Figure 3D) and insulin (Figure 3E)
levels were significantly reduced in the mutant mice, as were the
transcript levels of liver PEPCK and G6Pase (Figure 3F). How-Cell Meever, and in agreement with the fact that the NBR1MyKO mice
did not differ from their WT counterparts with respect to body
weight and adiposity, the metabolic changes in the context of
a HFD were not significantly different from those observed in
identically treated WT mice (Figures S2C–S2H). A wide range
of metabolic parameters was tested, including the whole-body
respiratory exchange ratio (RER), diurnal patterns of food and
water intake, locomotor activity, and calorie expenditure. There-
fore, although the loss of NBR1 in the myeloid compartment had
a significant impact on adipose tissue inflammation and glucose
homeostasis, it did not affect fat content or energy utilization at
the organismal level.
NBR1 Is Critical for M1 Differentiation and Macrophage
Activation Ex Vivo
In order to gain a more in-depth understanding of the mecha-
nisms whereby NBR1 regulates macrophage function in obesity,
we used an ex vivo system, whereby bone-marrow-derived
macrophages (BMDMs) were differentiated along the M1 or
M2 lineage. Adipocytes secrete type 2 cytokines, such as
IL-13 and IL-4, that skew ATMs toward the anti-inflammatory
M2 profile. In contrast to their M1 counterparts, which have a
proinflammatory profile, M2 ATMs counteract inflammation
in vivo. ATMs are induced to differentiate along the M1 lineage
when exposed to IFNg (Gordon, 2003; Kang et al., 2008; Ode-
gaard et al., 2008; Vats et al., 2006). Therefore, BMDMs of
both genotypes were incubated with IFNg or IL-13 to promote
M1 or M2 differentiation, respectively. Afterward, the expression
of specific markers of each lineage was determined by quantita-
tive RT-PCR. Notably, BMDMs from NBR1MyKO mice had a
dramatically reduced ability to respond to IFNg, as evident
from the low levels of induced IL-6, TNFa andNOS transcription,
but were sensitive to IL-13, as demonstrated by high levels of
Arg1 and Mgl2 transcription (Figures 4A and 4B). These results
are consistent with NBR1 being required for the differentiation
of macrophages along theM1, but not theM2, lineage and there-
fore being an important transducer of proinflammatory signals.
Consistent with this notion, the ability of BMDMs to induce IL-6
production, as measured at either the protein (Figure 4C) or
mRNA (Figure 4D) level, in response to endotoxin exposure (lipo-
polysaccharide [LPS]) was also severely blunted in NBR1-defi-
cient macrophages. In order to confirm these observations
and rule out hypothetical developmental defects in KO macro-
phages, macrophage-derived Raw cells were treated with either
a shRNA that effectively knocked down NBR1 levels (shNBR1;
Figure 4E, inset) or a control shRNA (shNT). Depletion of NBR1
in Raw cells resulted in impaired production of IL-6 in response
to LPS stimulation (Figure 4E), reinforcing the hypothesis that
NBR1 plays a critical role in the inflammatory activation of mac-
rophages. Because the loss of NBR1 in the myeloid compart-
ment reduced not only WAT inflammation but also the number
of macrophages in that tissue (Figures 2F–2I), we next tested if
the chemotactic response of the mutant macrophages was
affected. To this end, we performed migration assays using a
Boyden chamber and applying the chemoattractant MCP-1.
Both Raw cells depleted of NBR1 (Figure 4F) and NBR1MyKO
BMDMs (Figure 4G) exhibited severely reduced chemotactic
activity. Similar results were obtained with undifferentiated
monocytes (Figure S3). Collectively, these results demonstratetabolism 20, 499–511, September 2, 2014 ª2014 Elsevier Inc. 501
Figure 2. Myeloid-Specific Deletion of NBR1 Reduced ATM and Inflammation in HFD-Fed Mice
(A) Immunofluorescence staining for NBR1 (green), F4/80 (red), and DAPI (blue) in epididymal WAT of RD-fed mice (top) and HFD-fed mice (bottom). Colocal-
ization of NBR1 and F4/80 is shown in yellow in the merged image (n = 5 mice).
(legend continued on next page)
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NBR1-MEKK3, a Key Regulator of JNKthat NBR1 is a positive regulator of the cell-autonomous, proin-
flammatory functions of macrophages.
NBR1 Regulates the MEKK2/3-MKK4-JNK Pathway in
Macrophages
To begin to address the signaling pathway whereby NBR1 gov-
erns macrophage functions, BMDMs were stimulated with LPS
for various periods ranging up to 1 hr, and a number of signaling
parameters were evaluated. Whereas JNK activation was repro-
ducibly inhibited in the NBR1MyKO BMDMs (Figure 5A), neither
the activation of ERK (pERK) nor the phosphorylation and degra-
dation of IkB were affected (Figure 5A). NBR1 knockdown in the
macrophage-derived Raw cell line led to a similar suppression of
the JNK response to LPS treatment (Figure 5B). JNK is the main
MAPK activated upon inflammatory stress, and it has been asso-
ciated with glucose intolerance in HFD-treated mice (Hirosumi
et al., 2002). JNK is also required for the polarization of BMDMs
to the proinflammatory M1 phenotype. Moreover, its deletion in
macrophages reduces ATM infiltration as well as inflammation
and enhances the efficiency of glucose metabolism in the
context of obesity (Han et al., 2013; Sabio et al., 2008; Vallerie
et al., 2008). Therefore, our results demonstrating that NBR1
deficiency resulted in impaired JNK activation in macrophages
and that it improved glucose tolerance of mice with a myeloid-
specific KO establish NBR1 as a key regulator of JNK function
in the context of obesity-induced inflammation.
In the next series of experiments we investigated the mech-
anisms whereby NBR1 regulates JNK activation. Interestingly,
whereas activation of the JNK upstream kinase MKK4 was
severely suppressed in NBR1MyKO BMDMs, that of MKK3/6
was not affected (Figure 5C). When macrophages were stimu-
lated with palmitate, a saturated fatty acid abundant during
obesity, we found a robust activation of JNK in the WT cultures
but not in NBR1MyKO macrophages (Figure 5D). Notably, the
synthesis of IL-6 and TNFa was likewise induced by palmitate
treatment in WT but not in mutant macrophages (Figure 5E).
MKK7 was not activated in either the KO or in WT macro-
phages (data not shown). These results strongly suggest that
NBR1 positively regulates JNK through a direct or indirect
interaction with MKK4 and/or any of its upstream activators
(MAPKKKs).
PB1-Mediated Scaffold Role of NBR1 in Macrophages
As NBR1 contains a PB1 domain, we reasoned that its most
likely immediate target would be a PB1-containing MAPKKK,
MEKK2, or MEKK3. We further hypothesized that such an inter-(B) Quantitative analysis of relative expression of NBR1, asmeasured by RT-PCR u
mice).
(C) NBR1 expression in BMDMs (Mø), liver, epididymalWAT, and BAT ofWT and N
three experiments.
(D and E) (D) Body weight and (E) fat mass of WT and NBR1MyKO mice fed with
(F) Morphology andmyeloid infiltration ofWAT samples fromHFD-fedWT and NB
mice).
(G) Quantitative analysis of relative expression of markers of inflammation, as
NBR1MyKO mice (n = 6–8 mice).
(H) The stromal vascular fraction (SVF) of epididymal adipose tissue was isolated
cytometry to detect the total number of F4/80+ ATMs (n = 5 mice).
(I) Quantitative analysis of relative expression of markers of inflammation, as mea
mice (n = 5 mice). *p < 0.05; ***p < 0.001. Results are presented as mean ±SEM
Cell Meaction might involve direct contact between an acidic residue in
the NBR1 PB1 domain and a basic residue in the N-terminal
region of the MEKK2 or MEKK3 PB1 domain (Figure 6A) (Moscat
et al., 2006; Nakamura et al., 2010). Interestingly, MEKK3 (Fig-
ure 6B), similarly to NBR1 (Figure 2B), was upregulated in
ATMs isolated from HFD-fed mice as compared to those from
mice fed a regular chow diet. To test this possibility, we ectopi-
cally expressed HA-tagged MEKK2 or MEKK3 with Flag-tagged
NBR1 in human HEK293T cells and then assessed interactions
between NBR1 and these kinases by immunoprecipitation fol-
lowed by immunoblotting. The results in Figure 6C show that,
whereas Flag-tagged NBR1 was efficiently immunoprecipitated
with HA-tagged MEKK3, this was not the case for HA-tagged
MEKK2, establishing that NBR1 interacts specifically with
MEKK3. Notably, a D50R mutation in the PB1 domain of NBR1
completely abolished this interaction (Figure 6D). Figure 6E
demonstrates that endogenous NBR1 and MEKK3 likewise
interact physically.
In vitro studies using recombinant MKK4 protein demonstrate
that it was not able to interact with purified NBR1 in a pull-down
assay but that the addition of recombinant MEKK3 allowed the
coprecipitation of MKK4 and NBR1 (Figure S4A). Consistent
with the requirement of the PB1 for MEKK3 interaction with
NBR1, the NBR1-D50R mutant completely abolished the
in vitro coprecipitation of NBR1 with MKK4 (Figure S4A). In
agreement with these in vitro results, pull-down of ectopically
expressed GST-MKK4 resulted in coimmunoprecipitation of
ectopically expressed NBR1 and MEKK3 (Figure 6F). This dem-
onstrates that MEKK3 acts as a bridge to bring MKK4 and NBR1
together. To test the existence of this complex in an endogenous
setting, we next stimulated HEK293 cells stably expressing
hTLR4, MD2, and CD14 with LPS and then immunoprecipitated
endogenous NBR1. Western blotting revealed that the interac-
tion between NBR1 and MEKK3 was not inducible, but the inter-
action with MKK4 was (Figure 6G). Notably, treatment of BMDM
with palmitate resulted in enhanced expression of NBR1 and
MEKK3 (Figure 6H), in accordance with the data of Figures 2B
and 6B in ATMs from obesemice. More importantly, under these
conditions we also found a clear endogenous NBR1-MEKK3
interaction (Figure 6H). Thus, NBR1 appears to function as an
organizer of a MEKK3/MKK4 cassette that is required to activate
JNK and an obesity-induced inflammatory response. The fact
that the simple overexpression of NBR1 is sufficient to elevate
JNK activation to levels comparable to those observed following
stimulation with LPS (Figure 6I) further supports the notion that
the ability of NBR1 to nucleate a signaling complex is essentialsing total RNA isolated fromATMs of RD-fedmice andHFD-fedmice (n = 6–10
BR1MyKOmice, as assessed by western blotting. Results are representative of
HFD (n = 6–8 mice).
R1MyKOmice, as assessed by H&E staining and F4/80 immunostaining (n = 6–8
measured by RT-PCR assay using total RNA isolated from WAT of WT and
from WT and NBR1MyKO mice fed with HFD (4 weeks) and examined by flow
sured by RT-PCR using total RNA isolated from ATMs of WT and NBR1MyKO
. Scale bars, 50 mm. See also Figure S1.
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Figure 3. Myeloid-Specific Deletion of NBR1 Improved Glucose Clearance in HFD-Fed Mice
(A and B) Glucose tolerance test (GTT) (A) and insulin tolerance test (ITT) (B) in 8-week-old WT and NBR1MyKO mice fed a HFD for 4 weeks (n = 6–8 mice).
(C) WT and NBR1MyKO HFD-fed mice were fasted overnight and then treated by intraperitoneal injection with 1 U/kg insulin (15 min). Representative tissue
samples were examined by immunoblot analysis by probing with antibodies to phospho-AKT, AKT, and actin. Quantification of phospho-AKT is shown at bottom
(n = 5 mice).
(D and E) Blood concentration of glucose (D) and insulin (E) in overnight fasted mice HFD-fed WT and NBR1MyKO mice (n = 6–8 mice) were measured.
(F) Quantitative analysis of relative expression of PEPCK and G6Pase, as measured by RT-PCR using total RNA isolated from livers of HFD-fed WT and
NBR1MyKO mice (n = 6–8 mice). *p < 0.05; **p < 0.01; ***p < 0.001. Results are presented as mean ±SEM. See also Figure S2.
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NBR1-MEKK3, a Key Regulator of JNKfor the activation of JNK. In agreement with our hypothesis, the
knockdown of MEKK3 in BMDM led to reduced JNK activation,
as well as of IL-6 and TNFa synthesis, in response to palmitate
stimulation (Figures 6J and 6K). MLK3, another MAP3K like
MEKK3, has been shown be activated by saturated free fatty
acids and required for JNK activation in embryo fibroblasts, as504 Cell Metabolism 20, 499–511, September 2, 2014 ª2014 Elseviewell as in the adipose tissue of HFD-fed mice (Holzer et al.,
2011; Jaeschke and Davis, 2007). However, MLK3 deficiency
does not affect obesity or glucose homeostasis in HFD-fed
mice (Jaeschke and Davis, 2007). Our data demonstrate that
although MLK3 is activated in palmitate-treated macrophages,
this is independent of NBR1 (Figure S4B). Consistent with ar Inc.
Figure 4. NBR1 Deletion in Macrophages Impaired Macrophage Polarization toward the Proinflammatory M1 Phenotype
(A and B) Quantitative analysis of relative expression of markers of inflammation. Total RNAwas isolated fromBMDMs ofWT and NBR1MyKOmice and incubated
with either 100 ng/ml of IFNg for 8 hr or 10 ng/ml of IL-13 for 72 hr. The relative expression of the indicated markers of M1 (A) or M2 (B) polarization wasmeasured
by quantitative RT-PCR assay (n = 6 mice).
(C) IL-6 secretion by BMDMs from WT and NBR1MyKO mice fed with HFD for 12 weeks after LPS stimulation (100 ng/ml) for 3 hr (n = 4 mice).
(D) Relative expression of mRNA IL-6 by BMDMs from WT and NBR1MyKO mice after LPS stimulation for 8 hr (n = 6 mice).
(E) IL-6 secretion by shNT and shNBR1 Raw cells after LPS stimulation for 8 hr.
(F) Migration of shNT and shNBR1Rawcells after stimulation with the chemoattractantMCP-1 for 20 hr, as determined by amodified Boyden chamber assay. Left
panel: representative filters. Right panel: quantitation of data with total number of cells migrated indicated on y axis.
(G) Migration of BMDMs fromWT and NBR1MyKOmice, treated as in (F). Panels as in (F). Data are representative of three experiments. *p < 0.05; **p < 0.01; ***p <
0.001. Results are presented as mean ±SEM. Scale bars, 100 mm. See also Figure S3.
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NBR1-MEKK3, a Key Regulator of JNKfunctional role for the PB1 domains in the interaction between
NBR1 and MEKK3, the overexpression of NBR1 but not of a
PB1 mutant (D50R) activates JNK in cotransfection with
MEKK3 (Figure 6L). Interestingly, similar results were obtainedCell Mein palmitate-activated cells (Figure 6M). Furthermore, the re-
expression of NBR1 WT but not of NBR1-D50R reconstituted
JNK activation in response to palmitate in NBR1-deficient
BMDMs (Figure 6N).tabolism 20, 499–511, September 2, 2014 ª2014 Elsevier Inc. 505
Figure 5. NBR1 Deletion in Macrophages Downregulated the MEKK2/3-MKK4-JNK Pathway
(A–C) Western blot analysis with the indicated antibodies in BMDMs from WT and NBR1MyKO mice ([A] and [C]) or in shNT- and shNBR1-treated Raw cells (B)
stimulated with LPS (100 ng/ml) for the indicated time. Quantification of pJNK (A and B) and pMKK4 (C) fold change activation is shown in the right panels.
(legend continued on next page)
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Many studies have demonstrated that obesity-induced inflam-
mation plays a critical role in the generation of themetabolic syn-
drome, including a dysfunctional glucosemetabolism and insulin
resistance (Glass and Olefsky, 2012; Gregor and Hotamisligil,
2011). However, the precise signaling cascades accounting for
these effects still need to be identified, which is of great impor-
tance for the design of more efficacious treatments of type 2
diabetes. In this regard, JNK was recently recognized as an
important factor in obesity-induced inflammation, a condition
that contributes significantly to aberrant glucose metabolism in
obesity (Han et al., 2013; Lanuza-Masdeu et al., 2013; Sabio
et al., 2008; Vallerie et al., 2008; Zhang et al., 2011). The initial
observations were that JNK activity was abnormally elevated in
obesemice and that whole-body ablation of JNK1 resulted in de-
creases in body weight and adiposity in the context of a HFD
(Hirosumi et al., 2002; Tuncman et al., 2006). Although of great
relevance, those results did not distinguish between a role for
JNK activity in controlling the inflammation induced by obesity
from those effects specific to the control of adiposity itself
and obesity. Later studies, in which JNK1 was genetically and
selectively inactivated in adipocytes, established that this JNK
isoform plays a critical role in the inflammatory phenotype of
adipocytes and only a minor role in that of macrophages, in the
context of obesity-induced glucose intolerance (Sabio et al.,
2008). However, the most recent data from the same investiga-
tors demonstrated that simultaneous genetic inactivation of
both JNK1 and JNK2 in the myeloid compartment improved
glucose tolerance in these mice, although it did not affect the
bodyweight or adiposity (Han et al., 2013). Other potential mech-
anisms of action might include the implication of NBR1 in the
control of inflammation in b cell function. However, the fact
that insulin actions in ITT and phospho-Akt induction are
enhanced in response to insulin injection suggests that the
most likely main mechanism of action of macrophage NBR1 is
not by controlling insulin secretion. Collectively these data
demonstrated that JNK activation in macrophages is a critical
step in obesity-induced inflammation and glucose intolerance.
However, the upstream activators of this JNK activity in macro-
phages remained unknown. Our data in the present paper
demonstrate that the loss of NBR1 specifically in macrophages
largely prevents obesity-induced inflammation in vivo. More-
over, our ex vivo and in vitro results link the PB1 domain-medi-
ated interaction between NBR1 and MEKK3 to JNK activation
and the M1 polarization of macrophages.
These observations have to be put in the context of the other
PB1 domain proteins, p62 and PKCz, which have been also
implicated in the regulation of obesity and the metabolic alter-
ations associated to this physiopathological condition (Moscat
et al., 2006, 2007, 2009). In this regard, it is quite striking that
whereas p62 deficiency results in obesity and that the inflamma-
tion associated to the lack of p62 is secondary to increased
adiposity, the PKCz loss selectively promotes inflammation in(D) Western blot analysis with the indicated antibodies in BMDMs from WT and
indicated times. Quantification of pJNK fold change activation is shown in the rig
(E) Quantitative analysis of relative expression of markers of inflammation as meas
mice treated as in (D). Data are representative of three experiments. *p < 0.05; *
Cell Meobese mice without effects on adiposity (Mu¨ller et al., 2013;
Rodriguez et al., 2006). Interestingly, PKCz antiinflammatory
actions are mostly confined to the adipocyte, with no effects
on the hematopoietic system (Lee et al., 2010). In contrast,
NBR1 is a proinflammatory signaling adaptor in macrophages
by nucleating a MEKK3-driven JNK cascade, not only in
response to inflammatory signals such as LPS, but more impor-
tantly in response to saturated fatty acids like palmitate. The
mechanisms whereby palmitate promotes the accumulation of
NBR1, and MEKK3, are not known but will be very interesting
to address in future studies. Overall, these findings reveal a
potentially pharmacologically targetable mechanism underlying
JNK activation and suggest that blocking NBR1 binding to
MEKK3may represent an opportunity to prevent type 2 diabetes
in human obesity.EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Murine IFNg, IL-13, and MCP-1 were obtained from Peprotech, Inc. Lipopoly-
saccharide from Escherichia coli 0111:B4 was from Sigma-Aldrich. Gluta-
thione sepharose 4b, protein G sepharose 4 fast flow, and protein A sepharose
4 fast flow were from GE Healthcare Life Sciences. HisPur Cobalt resin was
from Thermo Scientific. EZview red anti-HA affinity gel was from Sigma-
Aldrich. Antibodies against HA (sc-805), myc (sc-40), NBR1 (sc-130380),
MEKK2 (sc-1088), MEKK4 (sc-166196), MKK4 (sc-837), MKK3/6 (sc-13069),
ERK1 (sc-94), p38 (sc-728), TAK1 (sc-7162), and AKT (sc-5298) were from
Santa Cruz Biotechnology. Antibodies against pMKK3/6 (#9231S), pMKK4
(#9151S), pMKK7 (#4171S), pJNK (#4668S), pERK (#4370S, pp38 (#9215S),
IkBalpha (#4814S), pIkBalpha (#9246S), and pAKT-S473 (#4058S) were from
Cell Signaling Technology. Flag (F3165) and b-actin (clone AC-74) antibodies
were from Sigma-Aldrich. Antibody against MEKK3 (m79820) was purchased
from BD Biosciences. p62 antibody (GP62-C) was from PROGEN Biotechnik
GmbH. Antibody against JNK (#551196) was purchased from PharMingen.
pCMV5-Flag-NBR1 and pWZL-Flag-NBR1 plasmids were obtained by sub-
cloning mouse NBR1 (NM_008676) into the pCMV5-Flag and pWZL-Flag vec-
tors, respectively. The point mutation resulting in an aspartic acid to arginine
substitution at position 50 (D50R) of the NBR1 PB1 domain was engineered
into the pCMV5-Flag-NBR1 and pWZL-Flag-NBR1 constructs using the
QuikChange site-directed mutagenesis kit (Stratagene) and NBR1D50 primers
(Table S2). pEBG-MKK4 (GST-MKK4) plasmid was from Addgene (Plasmid:
21563). pCMV-HA-MEKK2 and pCMV-HA-MEKK3 plasmids were a kind gift
from Dr. Frank S. Lee (University of Pennsylvania School of Medicine). MLK3
activity reagents were a kind gift fromDr. Ajay Rana (Loyola University Chicago
Stritch School of Medicine).
Mice
NBR1fl/fl mice were described previously (Yang et al., 2010). NBR1fl/fl mice
were bred to LysM-cre mice to generate myeloid-specific NBR1-KO
(NBR1MyKO). All genotyping was done by PCR. Animals were maintained
under controlled temperature (22.5C) and illumination (12 hr dark/light cycle).
Mice had free access to water and were fed either standard chow or high-fat
diets (45%-HFD; D12451 or 60%-HFD, D12492; Research Diets Inc.) ad libi-
tum. To assess glucose tolerance and insulin sensitivity, 8-week-old mice
were fed a standard chow or a 60% high-fat diet for 4 weeks. Mice were in-
jected intraperitoneally with 2 g glucose/kg body weight after overnight fasting
(25% D-glucose [Fisher Scientific] in 0.9% saline) for GTT assay. For ITT, mice
were injected with 0.5–0.75 U insulin/kg body weight (100 U/ml Novolin R
[Novo Nordisk]) after 6 hr fasting. Tail-blood glucose levels were measuredNBR1MyKO mice fed a HFD and stimulated with palmitate (0.8 mM) for the
ht panel.
ured by RT-PCR using total RNA isolated from BMDMs of WT and NBR1MyKO
*p < 0.01; ***p < 0.001. Results are presented as mean ±SEM.
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Figure 6. NBR1 Is a Scaffold for MEKK3 and MKK4
(A) Alignment of amino acid sequence of PB1 domains of mouse NBR1, MEKK2, and MEKK3. The secondary structural elements are shown above the
sequences. A conserved basic residue (B) and acidic residues (A) are boxed in green and orange, respectively. The potential interaction between acidic PB1
(PB1-A) of NBR1 and basic PB1 (PB1-B) of MEKK3, and the consequence of the D50R substitution in the PB1 domain of NBR1, are shown in the scheme below
the sequences.
(legend continued on next page)
Cell Metabolism
NBR1-MEKK3, a Key Regulator of JNK
508 Cell Metabolism 20, 499–511, September 2, 2014 ª2014 Elsevier Inc.
Cell Metabolism
NBR1-MEKK3, a Key Regulator of JNKby using an ACCU-CHEK Aviva (Roche) glucometer. Insulin concentration was
measured in plasma with a kit purchased from Crystal Chem. Measurements
of energy expenditure were performed using the indirect calorimetry Oxymax
system of the Comprehensive Lab Animal Monitoring System (CLAMS;
Columbus Instruments) at UCSD Animal Care Program in mice fed a 45%
HFD for 12 weeks. After adaptation for 24 hr, recordings were collected for
72 hr. The Institutional Animal Care and Utilization Committee approved all
procedures, in accordance with the NIH guide for the care and use of labora-
tory animals.
Human Studies
The clinical studies were reviewed and approved by the Pennington Biomed-
ical Research Center Institutional Review Board, and all subjects provided
written confirmation of informed consent.
Stromal Vascular Cell Isolation
Epididymal adipose tissue was excised and minced in 10 ml of HBSS solution
containing 0.5%BSA-Fatty acid free. Collagenase II (SigmaC6885, 0.5mg/ml)
was added, and the tissue was incubated at 37Cwith shaking (30min). A total
of 10 mM EDTA was added 5 min before the end of the incubation. Larger par-
ticles were removed using a 250 mm nylon sieves, and the filtrates were centri-
fuged at 5003 g for 5 min to separate floating adipocytes. The pelleted SVCs
were suspended in erythrocyte lysis buffer (155 mM NH4Cl, 10 mM KHCO3,
and 0.1 mM EDTA) and incubated at room temperature for 5 min. The erythro-
cyte-depleted SVCs were centrifuged at 5003 g for 5 min, and the pellet was
suspended in FACS buffer (PBS containing 25 mM HEPES, 2 mM EDTA, and
0.5% fetal bovine serum [FBS]). Enrichment of F4/80+ cells was performed by
magnetic immunoaffinity with F4/80-APC antibody (BM8, eBioscience) and
APC positive selection kit (StemCell Technologies).
Analysis of Tissue Sections
Histology was performed on WAT following fixation in 10% formalin for 24 hr,
dehydration, and embedding in paraffin. Sections (5 mm) were cut and stained
using hematoxylin and eosin (H&E). For immunohistochemical detection of
F4/80, sections were deparaffinized, rehydrated, and treated for antigen
retrieval. The Vector Mouse on Mouse (M.O.M.) immunodetection kit was
then used according to the manufacturer’s protocol (Vector Laboratories).
After blocking of endogenous peroxidase activity, the sections were incubated
in avidin/biotin blocking solution and M.O.M. mouse Ig-blocking reagent and
then with mouse monoclonal F4/80 antibody (#17-4801, eBioscience) for
30 min. The binding of primary antibody was detected using M.O.M. bio-
tinylated anti-mouse IgG and visualized using diaminobenzidine as the chro-
mogen. For immunofluorescence, sections were deparafinized as described(B) Quantitative analysis of relative expression of MEKK3, as measured by RT-PCR
10 mice).
(C and D) Interaction of NBR1 andMEKK3 through the PB1 domain. HEK293T cell
lysates and HA immunoprecipitates were analyzed by western blotting for Flag a
(E) Endogenous interaction of NBR1 andMEKK3was determined in immunoprecip
analyzed by immunoblot.
(F) NBR1 is a scaffold for MEKK3 and MKK4. HEK293T cells were transfected w
immunoprecipitates were analyzed by western blotting.
(G) Endogenous interaction of the NBR1-MEKK3-MKK4 complex in LPS-treated
were immunoprecipitated with anti-NBR1 antibody or control IgG. Cell lysates a
(H) Endogenous interaction of NBR1 and MEKK3 in palmitate-treated BMDMs. B
16 hr.
(I) Overexpression of NBR1 is sufficient to activate JNK. HEK293/hTLR4/MD2/CD1
Cell lysates were prepared and immunoblotted for the specified proteins.
(J) Western blot analysis of pJNK, JNK, and MEKK3 in BMDMs lentivirally infected
indicated times. Quantification of pJNK fold change activation is shown in the rig
(K) Quantitative analysis of relative expression ofmarkers of inflammation, asmeas
shRNA specific for MEKK3 and treated as in (J).
(L andM) Overexpression of NBR1 but not the PB1mutant NBR1-D50Rmediates
in 293T cells.
(N) Re-expression of NBR1WTbut not of NBR1-D50R reconstituted palmitate-ind
were reconstituted retrovirally wih FLAG-NBR1 or FLAG-NBR1(D50R) and treated
specified proteins. Results are representative of two experiments. **p < 0.01; ***
Cell Meabove and incubated with anti- NBR1 antibody (Thermo Scientific) 1:100
and anti-F4/80 (eBioscience) 1:50 overnight at 4C. Secondary antibodies
were then applied (Alexa fluor 568, A11011; Alexa fluor 488, A11006) 1:500
(Invitrogen). Stained sections were examined under an inverted laser scan
microscope (LSM 710 NLO, Zeiss, Germany).
Cell Culture
Raw and HEK293T cells were from ATCC. HEK293 hTLR4A/MD2/CD14 cells
were from InvivoGen (San Diego). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FCS, 2 mM L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. In the case of the hTLR4A/
MD2/CD14 HEK293 cells, 10 mg/ml blasticidin and 50 mg/ml hygromycin b
were added to growth medium as recommended by the manufacturer. The
detailed cell culture procedures are described in the Supplemental Experi-
mental Procedures.
Bone Marrow Macrophages
BMDMswere prepared by crushing mouse leg bones in DMEM supplemented
with 20% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM
L-glutamine. After being filtered through a 70 mm nylon mesh, cells were
plated in 10 cm dishes and incubated for 24 hr. Supernatants containing
bone marrow precursors were collected, centrifuged at 1,500 rpm, and
cultured in differentiation media (DMEM supplemented with 30% L929
supernatant, 15% fetal bovine serum, 5% horse serum, 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine, 0.1 mM nonessential amino
acids, 1 mM sodium pyruvate, and 0.5 mM b-mercaptoethanol). Polarization
studies were performed using BMDMs (8 days in culture) incubated with
100 ng/ml LPS, 0.8 mM Palmitate, 100 ng/ml IFNg (M1), or 10 ng/ml IL-13
(M2) for the indicated times.
Retroviral Transduction of Murine Bone Marrow
After 2 days of differentiation, adherent and nonadherent BM cells were
suspended in virus supernatants containing 5 mg/ml polybrene and seeded
in 6-well plates (2 3 106 cells per well). Plates were centrifuged 1 hr at
1,000 3 g and incubated at 37C and 5% CO2. After 24 hr the transduction
was repeated as before, suspending nonadherent cells in new virus superna-
tants that were combined with the other adherent cells. After 24 hr virus super-
natants were replaced with differentiation media and selection antibiotics.
Cells were replated after 4 days for the final experiment.
Cytokine Secretion
BMDMs or shNBR1 Raw cells were seeded into 6-well plates at 33 106 cells/
well. The next day, the cells were incubated for 1 hr with serum-free DMEM,using total RNA isolated from ATMs of RD-fedmice and HFD-fed mice (n = 6–
s were transfected with the indicated plasmids, cell lysates were prepared, and
nd HA.
itates fromRaw cells by anti-MEKK3 antibody or control IgG. Cell lysates were
ith the indicated plasmids, cell lysates were prepared, and lysates and GST
cells. HEK293/hTLR4/MD2/CD14 cells treated with LPS (100 ng/ml) for 30 min
nd immunoprecipitates were analyzed by immunoblotting.
MDMs were serum starved for 1 hr and stimulated with 0.8 mM palmitate for
4 cells were transfected with Flag-NBR1 and then stimulated with LPS as in (F).
with shRNA specific for MEKK3 and stimulated with palmitate (0.8 mM) for the
ht panel.
ured by RT-PCR using total RNA isolated fromBMDMs lentivirally infectedwith
JNK activation in cotransfection withMEKK3 (L) or after palmitate treatment (M)
uced JNK activation in NBR1-deficient BMDMs. BMDMs fromNBR1MyKOmice
with palmitate as in (J). Cell lysates were prepared and immunoblotted for the
p < 0.001. Results are presented as mean ±SEM. See also Figure S4.
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NBR1-MEKK3, a Key Regulator of JNKfollowed by 3 hr (BMDMs) or 8 hr (shNBR1 Raw cells) with or without 100 ng/ml
LPS. Supernatants were collected, filtered through a 0.45 mm mesh, and
subjected to IL-6 measurement using BD OptEIA Mouse IL-6 ELISA Kit
(BD Biosciences). Plasma levels of cytokines (MCP-1, TNFa, and IL-6) were
subjected to measurement using BD OptEIA Mouse IL-6 ELISA Kit and
Mouse TNFa ELISA kit (BD Biosciences) and eBioscience Mouse MCP-1
ELISA Ready-SET-Go! .
RNA Analysis
Total RNA from mouse tissues and cultured cells was isolated using the
TRI reagent (Molecular Research Center) and the RNeasy Mini Kit (QIAGEN),
followed by DNase treatment. After quantification using a Nanodrop 1000
spectrophotometer (Thermo Scientific), 1 mg of RNA was reverse-transcribed
using random primers and MultiScribe Reverse Transcriptase (Applied
Biosystems). Gene expression was analyzed by amplifying 50 ng of the com-
plementary DNA using the CFX96 Real Time PCR Detection System with
SYBR Green Master Mix (BioRad) and primers described in Table S2. The
amplification parameters were set at 95C for 30 s, 58C for 30 s, and 72C
for 30 s (40 cycles total). Gene expression values for each samplewere normal-
ized to the 18S RNA.
Statistical Analyses
Data are presented as the mean ±SEM. Differences between groups were
examined for statistical significance using nonparametric Mann-Whitney
test. The level of statistical significance was set at p < 0.05. All error bars repre-
sent SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2014.06.008.
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